Reported about 9 hours ago
Trexquant Investment LP has significantly reduced its stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) by 80.5%, leaving it with 18,694 shares valued at approximately $82,000. Despite this divestiture, Adverum continues to make progress in its ARTEMIS Phase 3 trial, gaining traction among retina specialists and patients, and actively seeking strategic partnerships. The company specializes in gene therapy for ocular diseases and remains a notable player in the biotechnology sector.
Source: YAHOO